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Tissue factor in cardiovascular diseases: molecular mechanisms
and clinical implications
Abstract
Tissue factor (TF), formerly known as thromboplastin, is the key initiator of the coagulation cascade; it
binds factor VIIa resulting in activation of factor IX and factor X, ultimately leading to fibrin formation.
TF expression and activity can be induced in endothelial cells, vascular smooth muscle cells, and
monocytes by various stimuli such as cytokines, growth factors, and biogenic amines. These mediators
act through diverse signal transduction mechanisms including MAP kinases, PI3-kinase, and protein
kinase C. Cellular TF is present in three pools as surface, encrypted, and intracellular protein. TF can
also be detected in the bloodstream, referred to as circulating or blood-borne TF. Elevated levels of TF
are observed in patients with cardiovascular risk factors such as hypertension, diabetes, dyslipidemia,
and smoking as well as in those with acute coronary syndromes. TF may indeed be involved in the
pathogenesis of atherosclerosis by promoting thrombus formation; in addition, it can induce migration
and proliferation of vascular smooth muscle cells. As a consequence, therapeutic strategies have been
developed to specifically interfere with the action of TF such as antibodies against TF, site-inactivated
factor VIIa, or recombinant TF pathway inhibitor. Inhibition of TF action appears to be an attractive
target for the treatment of cardiovascular diseases.
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Abstract 
 
Tissue factor (TF), formerly known as thromboplastin, is the key initiator of the 
coagulation cascade; it binds factor VIIa resulting in activation of factor IX and factor 
X, ultimately leading to fibrin formation. TF expression and activity can be induced in 
endothelial cells, vascular smooth muscle cells, and monocytes by various stimuli 
such as cytokines, growth factors, and biogenic amines. These mediators act 
through diverse signal transduction mechanisms including MAP kinases, PI3-kinase, 
and protein kinase C. Cellular TF is present in three pools as surface, encrypted, 
and intracellular protein. TF can also be detected in the bloodstream, referred to as 
circulating or blood-borne TF. Elevated levels of TF are observed in patients with 
cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, and 
smoking as well as in those with acute coronary syndromes. TF is indeed involved in 
the pathogenesis of atherosclerosis by promoting thrombus formation; in addition, it 
can induce migration and proliferation of vascular smooth muscle cells. As a 
consequence, therapeutic strategies have been developed to specifically interfere 
with the action of TF such as antibodies against TF, site-inactivated factor VIIa, or 
recombinant TF pathway inhibitor. Inhibition of TF action appears to be an attractive 
target for the treatment of cardiovascular diseases. 
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Introduction 
 
Tissue factor (TF) has long been known as a key initiator of the coagulation 
cascade. Over the last decade, our understanding of the molecular regulation of TF 
expression in vascular cells has profoundly improved; moreover, TF has been 
recognized to be involved in the pathogenesis of cardiovascular diseases. 
Therefore, therapeutic strategies are being developed to specifically interfere with 
TF and its effectors.  
We will review the molecular regulation of TF expression emphasizing the role 
of TF in cardiovascular diseases as well as the resulting implications for the 
treatment of atherosclerosis and acute coronary syndromes. 
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Molecular mechanisms of tissue factor expression 
 
 TF, formerly known as thromboplastin, is a 47 kD protein expressed in both 
vascular and non-vascular cells. The TF gene is located on chromosome 1 and 
consists of six exons.1 One main transcript as well as at least one alternatively 
spliced form have been described.2 In the vessel wall, TF is constitutively expressed 
in subendothelial cells such as vascular smooth muscle cells leading to rapid 
initiation of coagulation when the vessel is damaged.3 In contrast, endothelial cells 
and monocytes do not express TF under physiological conditions; as a 
consequence, there is no appreciable contact of cellular TF with the circulating 
blood. In response to various stimuli, however, TF expression and activity can be 
induced in these cells as well.  
The coagulation cascade is initiated as soon as TF comes into contact with 
circulating activated factor VII (VIIa) resulting in the TF-FVIIa complex (Fig. 1). 
Alternatively, TF can bind inactive factor VII and form the TF-FVII complex which is 
converted to TF-FVIIa by FVIIa or already formed TF-FVIIa. The TF-VIIa complex 
activates factor IX, which in turn activates factor X; alternatively, factor X is directly 
converted to factor Xa by TF-FVIIa. In complex with factor Va and calcium, Factor 
Xa catalyzes the conversion of prothrombin to thrombin, thereby leading to fibrin 
formation, platelet activation, and, ultimately, generation of a thrombus. Several of 
these activated proteases, including factor IXa, factor Xa, thrombin, and the TF-VIIa 
complex itself, can convert factor VII to VIIa in an auto-feedback loop. 
  In addition to its well established role in coagulation, TF participates in other 
cellular processes. It is involved in migration and proliferation of vascular smooth 
muscle cells.4 Furthermore, the development of embryonic blood vessels is critically 
dependent on TF as mice lacking TF die beyond embryonic day 8.5 secondary to 
abnormal circulation from yolk sac to embryo.5 TF has also been observed to 
promote tumor neovascularization and metastasis. 
Over the last years, our knowledge of the molecular mechanisms regulating 
TF expression as well as its biological action in vascular cells has greatly advanced 
and is delineated in this section. 
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Endothelial cells 
 Endothelial TF is induced by cytokines such as tumor necrosis factor-α (TNF-
α),6 interleukin-1β,7 or CD40 ligand,8 by biogenic amines such as serotonin9 or 
histamine,10 and by mediators like thrombin, oxidized LDL, or vascular endothelial 
growth factor (Fig.2).11-13 In spite of their diversity, most of these mediators share 
similar signal transduction pathways regulating TF induction. The MAP kinases p38, 
p44/42 (ERK), and c-jun terminal NHB2B-kinase (JNK) are involved in TNF-α-, 
histamine-, and thrombin-induced TF expression,6, 10, 12, 14 while the effect of VEGF 
is only mediated by p38 and ERK.14 TNF-α- and VEGF are known to induce TF 
expression via activation of protein kinase C as well.14 These signal transduction 
molecules stimulate the TF promoter by activating transcription factors such as AP-
1, NF-kB, and EGR-1,8, 14, 15 ultimately resulting in upregulation of TF mRNA.13, 15-17 
Regulation of the TF promoter is reviewed in detail elsewhere.15 
Unlike MAP kinases or protein kinase C, the PI3-kinase pathway negatively 
regulates endothelial TF expression; as a consequence, inhibition of PI3-kinase or 
its downstream mediators increases TF expression in response to TNF-α, histamine, 
thrombin, and VEGF.12, 16, 18, 19 The mechanism of the enhanced endothelial TF 
expression upon PI3-kinase inhibition has not yet been elucidated in detail. 
Downstream targets of PI3-kinase such as the mammalian target of rapamycin are 
known to be involved in the regulation of protein translation, which may at least in 
part account for their effect on TF expression.16 In one study, VEGF-induced p38 
activation was enhanced when PI3-kinase was blocked by wortmannin;19 hence, 
cross-talk to MAP kinases may explain the inhibitory role of the PI3-kinase pathway 
on VEGF-induced TF expression. In contrast, such cross-talk is not observed in 
response to thrombin16 indicating that the molecular events underlying the effect of 
PI3-kinase on endothelial TF expression differ with the particular stimulus involved. 
The extent of TF protein induction in vascular cells does not always correlate 
well with TF activity.10, 11 One possible explanation is the concomitant secretion of 
tissue factor pathway inhibitor (TFPI), the endogenous inhibitor of TF. Another 
possible reason is the distribution of TF into several cellular compartments.11, 20 
Biologically active TF is indeed located at the cell surface, while intracellular TF 
constitutes a pool which is only released upon cell damage. A combination of TNF-α 
and VEGF favors cell surface over intracellular distribution as compared to 
stimulation with either agonist alone, suggesting a complex regulation of the cellular 
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distribution of TF.11 Discrepancies between TF protein expression and activity can 
further be accounted for by the induction of a functionally inactive form of TF at the 
cell surface, termed latent or encrypted tissue factor. Expression of encrypted TF 
enables a cell to rapidly increase TF activity in response to certain stimuli without the 
need for de-novo protein synthesis, since de-encryption of TF has been observed 
secondary to changes in intracellular calcium levels, alterations in membrane 
phosphatidylserine expression, or modifications in the quaternary structure of TF.21 
Hence, the relative contribution of TF protein induction, cellular localization, and 
structural modification seems to determine the net procoagulant effect elicited by a 
given mediator. 
 
Vascular smooth muscle cells 
 In normal arteries, low levels of TF are found in the medial layer.3 Similarly, 
vascular smooth muscle cells in culture express low basal levels of TF.10, 20, 22, 23 
Mediators such as TNF-α, CD40 ligand, histamine, thrombin, endotoxin, and PDGF-
BB as well as aggregated low density lipoprotein and lysophosphatidic acid induce 
TF expression in vascular smooth muscle cells.10, 20, 22, 24-28 In general, the extent of 
inducibility in response to these mediators appears to be lower than that observed in 
endothelial cells or monocytes. Relatively few studies have investigated the 
molecular mechanisms regulating TF expression in vascular smooth muscle cells. 
Similar to endothelial cells, an involvement of MAP kinases and PI3-kinase has been 
observed. In human vascular smooth muscle cells, p38 and PI3-kinase mediate 
thrombin-induced TF expression.26 In rat vascular smooth muscle cells, ERK is 
involved in TF expression to lysophosphatidic acid28 and PDGF-BB,25 while p38 and 
PI3-kinase do not play a role. Hence, the effect of MAP kinases and the PI3 kinase 
pathway seems to depend on the particular stimulus and/or the species involved. 
Similar to endothelial cells, induction of vascular smooth muscle cell TF 
expression is only to some extent reflected in an increased TF activity.20 Consistent 
with this observation, vascular smooth muscle cell TF is found in three cellular pools, 
namely as surface TF, encrypted TF, and intracellular TF.20, 29  
 
Monocytes and macrophages 
 Monocytes, like endothelial cells, show very little to no basal expression of 
TF. Its expression can, however, be induced by inflammatory stimuli such as C-
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reactive protein30 or CD40 ligand.31 PDGF-BB, angiotensin II, and oxidized LDL32, 33 
have also been observed to induce TF in monocytes; yet one of the most extensively 
studied stimuli in this cell type is endotoxin.15, 34 p38, ERK, and JNK are all involved 
in lipopolysacharide-induced monocyte TF expression34 leading to nuclear 
translocation of the transcription factors EGR-1, c-Fos/c-Jun, and c-Rel/p65. 
Ultimately, binding of these transcription factors to the EGR-1, AP-1, and NF-kB 
sites of the TF promoter mediates the endotoxin-induced increase in TF mRNA 
transcription.15 Similar to endothelial cells, the PI3 kinase pathway exerts an 
inhibitory influence on TF induction in this cell type, and at least part of this action 
occurs through cross-talk with MAP kinases.34 
Type 1 (THB1), but not type 2 helper T cells (THB2B), secrete mainly pro-
inflammatory mediators such as TNF-α and IFN-γ, which are involved in 
macrophage activation.35 Cytokines derived from THB1B cells as well as cell-to-cell 
contact with THB1B cells induces TF expression in monocytes.36 Transformation of 
monocyte-derived macrophages into foam cells results in increased TF expression 
as well.37 In contrast, THB2B-derived mediators such as Il-4, Il-10, and Il-13 prevent 
THB1B-induced TF expression.36 Thus, consistent with their role in macrophage 
activation and atherogenesis, pro-inflammatory stimuli released from THB1B cells 
upregulate TF expression, while cytokines derived from THB2B cells inhibit this effect. 
 
 
Blood-borne tissue factor 
TF is not only present in vascular cells or leucocytes, but can also be 
detected in the bloodstream, referred to as circulating or blood-borne TF.38 This form 
of TF is mainly associated with microparticles39 originating from endothelial cells, 
vascular smooth muscle cells, leukocytes, or platelets.22, 40 In addition, TF containing 
microparticles are released from atherosclerotic plaques.39  
Monocytes and platelets are known to exchange microparticle-bound TF.41 
Since megakaryocytes, the bone-marrow sedentary precursors of platelets, do not 
express TF, it is likely that this exchange represents a mechanism through which 
platelets are loaded with TF. In addition to carrying microparticle-derived TF, 
activated platelets induce tissue factor expression in human endothelial and smooth 
muscle cells, presumably by releasing soluble mediators such as serotonin and 
PDGF.42 Aggregating platelets thus induce a positive feedback loop which enhances 
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local TF concentrations via two mechanisms and may be important for thrombus 
formation and / or propagation. 
Recently, an alternatively spliced form of TF has been discovered, which is 
soluble, circulates in the blood, and exhibits pro-coagulant activity.2 Cytokines 
stimulate its expression in and release from endothelial cells.43 Alternatively spliced 
TF is not bound to microparticles and seems to represent a distinct form of 
circulating TF; as such, it may have an important role in thrombus propagation.43 
Indeed, soluble TF may be particularly important in this context, as vessel wall-
associated TF, being separated from the bloodstream by the freshly formed 
thrombus, may be prevented from contributing to thrombus growth.44 
These studies on blood-borne TF imply that activation of coagulation, contrary 
to traditional belief, may be initiated and propagated without contact of the blood to 
the extravascular space. The importance of blood-borne versus vessel wall-
associated TF is currently a subject of debate.44-46 One study described that TF from 
leukocyte-derived microparticles importantly contributes to thrombus propagation in 
an animal model of thrombosis,44 while another one identified vessel wall-derived TF 
as the primary mediator driving thrombus formation after vascular injury.45 It is also 
controversial whether physiological concentrations of circulating TF can exhibit clot-
forming activity in vivo.47 Thus, the relative contribution of soluble TF, microparticle-
bound TF, and vessel wall-associated TF to initiation and propagation of thrombosis 
requires further study.  
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Tissue factor in cardiovascular diseases 
 
Tissue factor has been implicated in the pathogenesis of several 
cardiovascular disorders. The following section summarizes its involvement in 
cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, and 
smoking; its role in atherosclerosis and acute coronary syndromes is discussed as 
well. 
 
Cardiovascular risk factors 
TF plasma antigen is elevated in hypertensive subjects as compared to 
normotensive controls and can be lowered by different classes of antihypertensive 
drugs.48 Of particular interest is the observation that angiotensin II induces TF 
expression in monocytes, endothelial cells, and vascular smooth muscle cells24, 32 
via the angiotensin II type I receptor (AT-I)32. Consistently, both ACE inhibitors49 and 
AT-I receptor blockers50 reduce TF plasma activity in hypertensive patients. ACE 
inhibitors also reduce endotoxin-induced TF expression in monocytes,51 suggesting 
a pleiotropic effect of this class of drugs.  
High glucose concentrations increase thrombin-induced TF expression in 
human endothelial cells.52 Similarly, glucose intake upregulates TF expression in 
monocytes of healthy humans. Hyperglycemia leads to the formation of advanced 
glycation end-products (AGE), which induce TF expression in endothelial cells via 
the receptor for advanced glycation end-products (RAGE) and activation of NF-kB.53, 
54
 Consistent with this observation, diabetic ApoE-/- mice display increased vascular 
expression of RAGE and TF;55 moreover, blockade of RAGE suppresses TF levels 
in the aorta of these mice, which may have interesting implications for the 
pathogenesis and treatment of diabetic vasculopathy.55 In diabetic patients, 
increased TF plasma levels are measured even without overt coronary artery 
disease,56 and TF levels are reduced by improving glycemic control.57 In obese non-
diabetic subjects, insulin reduces both monocyte TF expression and TF plasma 
levels, which occurs due to a reduced activation of the pro-inflammatory transcription 
factor EGR-1, suggesting that insulin exerts its beneficial effects not only via 
improving hyperglycemia.58  
Oxidized low-density lipoprotein increases TF expression in endothelial 
cells,13 monocytes, and macrophages,33 while reconstituted high-density lipoprotein 
Steffel et al., Circulation 2006   
  10 / 38 
inhibits thrombin-induced endothelial TF expression.18 Consistent with these 
observations, patients with elevated low-density lipoprotein levels display raised TF 
plasma activity.57 HMG-CoA reductase inhibitors (statins), the most widely used 
drugs for the treatment of hypercholesterolemia, reduce TF expression in 
monocytes, endothelial cells, and vascular smooth muscle cells.12, 59 In apoE 
knockout mice, simvastatin inhibits TF expression in advanced atherosclerotic 
lesions independent of plasma lipid levels.60 Hence, the reduction of TF expression 
by statins is at least in part related to the pleiotropic anti-inflammatory effects of this 
class of drugs. Consistent with this interpretation, endotoxin-induced TF expression 
is blunted after administration of simvastatin to healthy humans.61 Fibric acid 
derivatives are another class of drugs used to treat patients with dyslipidemia. 
Through activation of the peroxisome proliferator-activated receptor-alpha 
(PPARalpha), these drugs reduce TF expression in human monocytes and 
macrophages, which may in part be responsible for their beneficial effect in patients 
with cardiovascular diseases.62 
Exposure of apoE knockout mice to cigarette smoke results in an increased 
TF expression in atherosclerotic plaques as compared to mice breathing filtered 
room air.63 Cigarette smoking is associated with increased TF plasma levels in 
humans as well; indeed, a strong correlation is observed between the number of 
cigarettes smoked and TF plasma levels.57  
These data indicate that TF may be involved in the pro-atherosclerotic effect 
of cardiovascular risk factors. It cannot be ruled out, however, that some of the 
observed elevations in TF plasma levels occur secondary to TF release from already 
established atherosclerotic plaques.  
 
Atherosclerosis 
 Monocytes infiltrate the intimal layer and then transform into macrophages 
and foam cells, which represents a hallmark of the inflammatory nature of 
atherosclerosis.35 In this inflammatory environment, cytokines such as TNF-α and 
interleukins are released and induce expression of TF. During the early stages of 
atherogenesis, enhanced TF expression is observed in monocytes3; at later stages, 
TF expression is also detected in foam cells, endothelial cells, and smooth muscle 
cells.3, 64 TF is present in the necrotic core of plaques as well, predominantly 
associated with microparticles derived from perishing foam cells, macrophages, or 
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lymphocytes.39, 64 Such microparticles indeed contain the major part of the TF 
activity in atherosclerotic plaques.39 Consistent with these observations, TF 
expression is closely associated with apoptosis of macrophages in lipid-rich 
plaques,65 which adds to the evidence that not only inflammation, but also apoptosis 
can determine plaque thrombogenicity. 
 Increasing size of atherosclerotic plaques can lead to vascular stenosis, 
which is associated with enhanced shear forces promoting endothelial TF 
expression. In most instances, however, it is not the degree of luminal narrowing, but 
rather the composition of the plaque which determines the clinical course of events. 
Lipid-rich plaques with a thin cap, a large lipid core, extensive macrophage 
infiltration, and abundant TF expression are more prone to rupture than collagen-
rich, fibrous plaques. Rupture of an atherosclerotic plaque exposes its highly 
procoagulant content to the circulating blood; thereby, TF-laden macrophages as 
well as TF-containing microparticles originating from the necrotic core initiate 
thrombus formation and related complications such as acute myocardial infarction 
(Fig. 3). 
 Besides activation of the coagulation cascade, TF is involved in other 
pathogenetic events occurring during the formation of atherosclerotic lesions. TF is 
the receptor for factor VIIa and as such mediates responses like migration66 and 
proliferation of vascular smoothP Pmuscle cells.67 These processes are importantly 
involved in vascular remodeling, since vascular smooth muscle cells migrate into 
and proliferate within the neointima of injured vessels. The effect of the TF/FVIIa 
complex on migration and proliferation of vascular smooth muscle cells is critically 
dependent on the cytoplasmic domain of TF, as vascular remodeling in response to 
injury is reduced in mice lacking this domain.68 Recruitment of microvessels into 
atherosclerotic plaques can lead to plaque progression by contributing to plaque 
destabilization and rupture.35 As TF is involved in angiogenesis,5 it may also play a 
role in plaque neovascularization and thereby promote plaque destabilization. Thus, 
evidence is emerging that TF may not only be involved in atherogenesis by eliciting 
thrombosis, but also by direct actions on vascular remodeling and plaque 
progression or instability. 
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Acute coronary syndrome and percutaneous coronary intervention 
 Increased levels of TF antigen and activity are detected in atherectomy 
specimens from patients with unstable angina or myocardial infarction as compared 
to those with stable angina.69 In acute coronary syndromes, plasma concentrations 
of inflammatory cytokines such as TNF-α and interleukins are indeed increased at 
the site of coronary artery occlusion to such an extent that TF is induced in vascular 
cells.70 Hence, vascular cells as well as circulating leucocytes and aggregating 
platelets may be a source of the elevated levels of circulating TF measured in 
patients with acute coronary syndrome.71 As plaque rupture leads to exposure of 
highly procoagulant plaque content to the circulation, it may also contribute to the 
elevated TF plasma levels.39 Consistent with this interpretation, patients with 
unstable angina show higher TF plasma levels than those with stable angina,72 and 
elevated TF plasma levels may even predict future cardiovascular events in patients 
with unstable angina.72 As a substantial number of patients with acute myocardial 
infarction develop coronary artery thrombi on top of a superficial erosion, increased 
TF plasma levels in these patients may also originate from endothelial erosions of 
atherosclerotic lesions.73 Interestingly, several polymorphisms of the TF gene are 
known, and recent data suggest that certain genetic variations in the TF gene as 
well as the TF promoter may be associated with a worse outcome in patients with 
acute coronary syndrome, possibly through increased monocyte TF expression.74, 75  
Selective cyclooxygenase-2 inhibitors (coxibs), rofecoxib in particular, have 
come under scrutiny as they are suspected of causing thrombotic complications in 
patients with cardiovascular diseases. This effect is believed to depend on inhibition 
of prostacyclin formation. Large-scale epidemiological studies have indeed 
suggested that rofecoxib intake is associated with an increased risk of myocardial 
infarction.76 This association, however, is not observed with celecoxib, which may be 
related to inhibition of TF expression by this coxib in endothelial cells.6 Given the 
importance of TF in the pathogenesis of acute coronary syndromes, this effect may 
account for the different occurrence of thrombotic complications between coxibs 
observed in epidemiological studies.76 As neither rofecoxib nor the experimental 
coxib NS-398 inhibit endothelial TF expression, the effect of celecoxib appears to 
occur independent of cyclooxygenase inhibition; instead, it is mediated by 
decreasing TNF-α-induced JNK phosphorylation.6 
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As platelets represent a major source of TF, it is conceivable that antiplatelet 
drugs, which are used for treating acute coronary syndromes, reduce TF expression 
as well as TF plasma levels. Indeed, the ADP receptor antagonist clopidogrel 
reduces TF expression in the ischemic coronary artery in an animal model of acute 
myocardial infarction.77 Moreover, as interaction with platelets induces TF 
expression in monocytes, the GPIIb/IIIa antagonist abciximab suppresses monocyte 
TF expression and activity by reducing platelet-monocyte cross talk; likewise, 
abciximab reduces monocyte TF expression in patients undergoing carotid 
angioplasty with stenting.78 Aspirin, however, inhibits endotoxin-induced 
transcriptional activation of TF expression in monocytes and may thus reduce TF 
plasma activity by direct actions on the regulation of TF expression as well.79 In 
contrast to these agents, long-term treatment with the oral anticoagulant warfarin 
increases soluble TF levels, probably due to decreased TF consumption.80  
Percutaneous coronary intervention is the preferred treatment for patients 
presenting with acute myocardial infarction. It is unclear whether or not TF plasma 
levels are increased after percutaneous coronary intervention, as some groups 
found an increase while others did not.81 It is conceivable that plaque dissection due 
to balloon dilatation may lead to exposure of plaque content to the bloodstream and 
thereby increase TF plasma levels. In the reperfusion phase, oxygen-derived free 
radicals were observed to mediate TF induction, while continuous inflammatory 
alterations of the atherosclerotic coronary arteries may increase TF levels at later 
stages.82 If present, increased TF levels have a negative prognostic value regarding 
the development of restenosis after percutaneous coronary angioplasty with or 
without stenting.81 This effect may well be related to the pro-migratory and pro-
proliferative action of TF on vascular smooth muscle cells, which are known to 
contribute to the development of restenosis.4, 66, 67 
 Drug-eluting stents are covered with pharmacological agents which, once 
released into the coronary artery after stent deployment, inhibit vascular smooth 
muscle cell proliferation and thereby restenosis. In contrast to reduced restenosis 
rates, however, the frequency of stent thromboses has not decreased with drug-
eluting stents as compared to bare metal stents.83 Rapamycin, which is used for 
stent coating, increases endothelial TF expression, suggesting a potential role for 
this drug in the development of subacute stent thrombosis.16 As this effect on TF 
expression is not observed with FK-506, another agent used on drug-eluting stents, 
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application of FK-506-eluting stents may provide a more favorable environment 
regarding the development of in-stent thrombosis.16 However, additional studies are 
needed to assess the implications of these findings in vivo. Platelet activation is a 
crucial event in the pathogenesis of thrombus formation. The use of platelet receptor 
antagonists such as clopidogrel has indeed reduced the incidence of stent 
thrombosis, while withdrawal of antiplatelet therapy favors thrombus formation.83 
Clopidogrel inhibits the release of TF from aggregating platelets, which is of 
particular importance, as platelet aggregation and secretion are increased in human 
platelets treated with rapamycin.84 Therefore, it will be of great interest to study the 
dynamic interaction between rapamycin and platelet activation as well as the spatio-
temporal pattern of tissue-factor expression in the arterial wall after deployment of 
drug-eluting stents. 
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Therapeutic implications 
 
Various agents have been developed to specifically interfere with the action of 
TF and the TF/FVIIa complex (Fig. 4). In contrast to classical antithrombotic drugs, 
these agents target the first steps of coagulation while leaving the downstream 
effectors intact. In addition, these drugs can interfere with pro-migratory or pro-
proliferative effects of TF. In this section, we will focus on recently developed drugs 
specifically targeting TF, while non-specific inhibitors will not be discussed. 
 
Inhibition of TF synthesis 
 A hairpin ribozyme, which destroys TF mRNA, abrogated induction of TF 
protein expression and activity in vascular smooth muscle cells.85 Similarly, 
antisense oligonucleotides, hybridizing to their complementary target mRNA and 
thereby preventing translation, inhibited TF induction in monocytes.86 An alternative 
approach takes advantage of curcumin, a naturally occurring pigment suppressing 
the activation of the transcription factors Egr-1, AP-1, and NF-kB, and resulting in 
inhibition of TNF-α-induced endothelial TF induction.87 Although novel and intriguing, 
the clinical applicability of these approaches has not yet been examined. 
 
Direct inhibition of TF action 
Different antibody preparations directed against the TF antigen (TF Ab) have 
been tested in vivo. In a rabbit carotid artery thrombosis model, a monoclonal anti-
TF Ab inhibited thrombus formation and shortened tissue plasminogen activator lysis 
time.88 Similarly, administration of a monoclonal anti-TF Ab reduced infarct size in a 
rabbit coronary artery ligation model due to reduced chemokine expression and 
leukocyte infiltration.89 In humans, a polyclonal anti-TF Ab reduced thrombogenicity 
of disrupted atherosclerotic plaques by impairing platelet and fibrin deposition.90 In a 
recent dose-escalating trial, a chimaeric monoclonal anti-TF Ab potently inhibited 
thrombin formation in patients with stable coronary artery disease.91 
An alternative approach consists of a mutant form of TF, which binds to factor 
VIIa but exhibits reduced catalytic activity.92 In a rabbit model of arterial thrombosis, 
this protein displayed potent antithrombotic properties while causing less bleeding 
than heparin.92 Another mutated form of TF exhibited antithrombotic properties in a 
guinea pig model of recurrent arterial thrombosis.93 
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Active-site inactivated factor VIIa 
 Active-site inactivated factor VIIa (FVIIai) binds to TF, but lacks catalytic 
activity; as such, it competes for TF with the physiologically occurring form of factor 
VIIa. Several animal studies examined the effect of FVIIai in vivo, demonstrating 
decreased recurrent arterial thrombosis, reduced infarct size, and improved no-
reflow phenomenon; after administration of a single dose, the effect of FVIIai was 
long-lasting without affecting systemic hemostatic parameters.94 Application of a 
structurally different, but functionally similar site-inactivated factor VIIa compound 
reduced restenosis in a femoral artery injury model,95 which may in part be due to 
the fact that TF as well as several downstream coagulation factors stimulate 
vascular smooth muscle cell migration and proliferation.66, 67  
 
Recombinant tissue factor pathway inhibitor 
TF activity is counterbalanced by its endogenous inhibitor, tissue factor 
pathway inhibitor (TFPI). TFPI interferes with activity of the TF/FVIIa complex by 
binding to the active site of FXa leading to formation of a quaternary complex with 
TF/FVIIa. Under physiological conditions, TFPI is mainly synthesized and released 
by endothelial cells. In animal models, recombinant TFPI (rTFPI) reduced fibrin 
deposition and neointimal thickening after balloon injury.96 In human atherosclerotic 
arteries, rTFPI diminished plaque thrombogenicity by inhibiting platelet and fibrin 
deposition.90 
Adenoviral gene transfer represents an alternative approach for application of 
a recombinant protein.97 Adenoviral overexpression of TFPI in injured arteries 
inhibited recurrent thrombosis induced by shear stress without affecting systemic 
coagulation parameters.98 Similarly, overexpression of TFPI reduced 
thrombogenicity as well as vascular remodelling of balloon-injured atherosclerotic 
arteries.99 
Based on these observations, clinical studies have investigated the safety and 
efficacy of rTFPI. Initial trials revealed promising results in various settings; a double 
blind, randomized, phase III trial in patients with severe sepsis and mild 
coagulopathy, however, failed to show a clinical benefit of rTFPI, while the frequency 
of severe adverse events with bleeding was increased.100 Further studies are 
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needed to definitively assess the safety and efficacy of rTFPI as a therapeutic 
principle. 
 
Nematode anticoagulant protein c2 
 Nematode anticoagulant protein c2 (NAPc2) is isolated from the saliva of the 
hookworm Ancylostoma caninum; it interferes with TF activity by binding to factor Xa 
or factor X prior to formation of a quarternary inhibitory complex with TF/FVIIa. 
Several studies in primates as well as first studies in humans revealed very 
promising results; in a phase II clinical trial, rNAPc2 indeed appeared safe and 
effective in preventing thrombin generation during coronary angioplasty in 
combination with aspirin, clopidogrel, and heparin.101  
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Summary & Conclusions 
 
Over the last years, major advances have been made in elucidating the 
molecular regulation of TF expression. Various cytokines, growth factors, and 
biogenic amines have been recognized to induce TF expression in endothelial cells, 
vascular smooth muscle cells, and monocytes. Signal transduction mechanisms 
specific for both the cell-type and the stimulus involved regulate TF induction and 
cellular distribution. In addition to cellular TF, an important role of blood-borne TF is 
emerging; at present, however, the relative contribution of vessel wall-associated 
versus blood-borne TF to thrombus formation and / or propagation is debated. 
Patients with cardiovascular risk factors such as hypertension, diabetes, 
dyslipidemia, and smoking have elevated plasma levels of TF, which may be 
involved in the pro-atherosclerotic effect of such risk factors. Moreover, TF 
expression is upregulated in the inflammatory environment of atherosclerotic 
plaques, and large amounts of TF are released during plaque rupture, leading to 
thrombus formation and elevated TF plasma levels in patients with unstable angina 
and acute coronary syndromes. As TF simulates vascular smooth muscle cell 
migration and proliferation, it may promote atherogenesis and restenosis not only by 
initiating thrombosis, but also by direct actions on vascular remodeling and plaque 
progression. 
Several promising therapeutic strategies have been developed for targeting 
the action of TF including antibodies against TF, site-inactivated factor VIIa, 
recombinant TFPI, and recombinant NAPc2. Despite recent set backs with 
application of rTFPI, interfering with the TF pathway appears to be an attractive 
target for the treatment of cardiovascular diseases. 
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Figure legends 
 
Figure 1: Tissue factor – A key regulator of coagulation 
Tissue Factor (TF) is a key initiator of the coagulation cascade. Formation of 
a complex with factor VIIa (FVIIa) leads to activation of factor IX (FIX) and factor X 
(FX), resulting in thrombin generation and, ultimately, clot formation. Tissue factor 
pathway inhibitor (TFPI), the endogenous inhibitor of TF activity, is synthesized and 
secreted mainly by endothelial cells. TFPI binds to FXa and thereby inhibits TF/FVIIa 
activity.  
 
Figure 2: Induction of tissue factor expression and activity 
Induction of tissue factor (TF) is exemplified in an endothelial cell. Various 
mediators induce TF expression through activation of their receptors. Induction of TF 
primarily occurs at the transcriptional level, resulting in an increase in TF mRNA and, 
eventually, TF protein expression. TF is distributed in three cellular pools as 
cytoplasmatic TF, surface TF, and encrypted TF. Moreover, TF-containing 
microparticles are released from the cell. Alternative splicing results in a soluble 
secreted form of TF (asTF). Il-1β: Interleukin 1β; LPS: Lipopolysacharide; TNF-α: 
Tumor necrosis factor α; VEGF: Vascular endothelial growth factor; HB1B: Histamine 
HB1B-receptor; 5-HTB2aB: 5-HydroxytryptamineB2aB receptor; Il1-R: Interleukin-1 receptor; 
TLR-4: Toll-like receptor 4; PAR: Protease-activated receptor; KDR: VEGF receptor-
2. 
 
Figure 3: Tissue factor in the atherosclerotic plaque 
In the inflammatory environment of atherosclerotic plaques, tissue factor (TF) 
is present at high levels in endothelial cells, vascular smooth muscle cells, 
macrophages/foam cells, and in the necrotic core. TF induction is exemplified by 
selected mediators in endothelial cells (EC, left panel), macrophages (MΦ, middle 
panel), and vascular smooth muscle cells (VSMC, right panel). Upon plaque rupture, 
highly procoagulant material including TF-containing microparticles is released into 
the blood leading to rapid initiation of coagulation, platelet aggregation, and, 
ultimately, thrombus formation with vessel occlusion.  
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Figure 4: Therapeutic approaches 
Several therapeutic strategies have been developed to specifically interfere 
with the action of tissue factor (TF). Molecular approaches such as ribozymes or 
antisense oligonucleotides specifically inhibit TF production. Mono- or polyclonal 
anti-TF antibodies directly target and inactivate the TF protein. Site-inactivated factor 
VIIa (FVIIai) binds to TF, but lacks catalytic activity for conversion of factor X (FX) or 
factor IX (FIX). Recombinant tissue factor pathway inhibitor (rTFPI) interferes with 
the activity of the TF/FVIIa complex by binding to the active site of factor Xa (FXa) 
leading to formation of a quaternary inhibitory complex with TF/FVIIa. Similarly, 
recombinant nematode anticoagulant protein c2 (rNAPc2) interferes with the 
TF/FVIIa complex by binding to FXa or FX prior to formation of a quarternary 
inhibitory complex with TF/FVIIa. 
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